Optimization protocol for amyloid‐β peptides detection in human cerebrospinal fluid using SELDI TOF MS

Valentina Albertini(Centro San Giovanni di Dio Fatebenefratelli), Roberta Ghidoni(Centro San Giovanni di Dio Fatebenefratelli), Anna Paterlini(Centro San Giovanni di Dio Fatebenefratelli), Anna Bruno(Centro San Giovanni di Dio Fatebenefratelli), Cristina Cereda(University of Milan), Simone Lista(Universidad Europea Miguel de Cervantes), Giuliano Binetti(Centro San Giovanni di Dio Fatebenefratelli), Luisa Benussi(Centro San Giovanni di Dio Fatebenefratelli)
PROTEOMICS - CLINICAL APPLICATIONS
January 28, 2010
10.1002/prca.200900166
Cited by 27

Related Papers

New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Characterization of human disease phenotypes associated with mutations in <i>TREX1</i>, <i>RNASEH2A</i>, <i>RNASEH2B</i>, <i>RNASEH2C</i>, <i>SAMHD1</i>, <i>ADAR</i>, and <i>IFIH1</i>
|American Journal of Medical Genetics Part A|2015|617
Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology
|Nature Genetics|2021|567
Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study
|The Lancet Neurology|2013|441